Trial Profile
An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonvalvular atrial fibrillation.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Certoparin sodium (Primary)
- Indications Embolism and thrombosis
- Focus Adverse reactions
- Acronyms AFFECT
- 31 Aug 2010 Actual end date (August 2006) added as reported by ClinicalTrials.gov.
- 21 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 09 Jan 2007 Status change